Edwards Lifesciences (NYSE:EW) Upgraded at StockNews.com

StockNews.com upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a report released on Thursday.

Other equities research analysts also recently issued research reports about the company. OTR Global upgraded Edwards Lifesciences from a mixed rating to a positive rating in a research report on Tuesday, March 26th. Royal Bank of Canada lifted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an outperform rating in a research report on Monday, April 15th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an overweight rating in a report on Thursday, March 21st. Piper Sandler boosted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company a neutral rating in a report on Friday, April 26th. Finally, Evercore ISI cut their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an in-line rating on the stock in a report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of Moderate Buy and an average target price of $95.06.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $92.37 on Thursday. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The company has a market cap of $55.66 billion, a price-to-earnings ratio of 39.81, a PEG ratio of 3.41 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The business’s 50 day moving average price is $87.85 and its 200 day moving average price is $85.30.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. On average, research analysts predict that Edwards Lifesciences will post 2.77 EPS for the current year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The disclosure for this sale can be found here. Insiders sold 127,104 shares of company stock valued at $11,267,464 in the last three months. 1.29% of the stock is owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

A number of large investors have recently made changes to their positions in EW. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $28,000. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $34,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $34,000. Finally, Pingora Partners LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $38,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.